BGB-C354

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameBGB-C354
Drug Alias NameBGB-C354BG-C354
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-CD276DNA topoisomerase I inhibitors
TargetsCD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursLung NeoplasmsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdBeOne Medicines LtdBeOne Medicines (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A